Viking Therapeutics ' (NASDAQ: VKTX) shares could rise over the next year by as much as 165% at the midpoint according to ...

Funds should be able to invest more in promising local innovations, keeping IP in Australia and boosting productivity while ...

The pharmaceutical industry continues to evolve rapidly, driven by innovation, global health challenges, and technological ...

Foreign firms showed mixed reactions to the decision, with some willing to offload a 5% stake while others were not ...

Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust ...

The French pharmaceutical company claims that Sarclisa-VRD showed great improvement in the minimum residual disease (MRD) ...

He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

BENGALURU] European stocks logged their biggest one-day drop in over three months on Friday (Aug 1), at the end of a busy ...

Experts are skeptical that Big Pharma companies will cut prices after President Donald Trump demands Most Favored Nation policies within 60 days.

U.S. sales of Eylea HD and Eylea, treatments for eye conditions like wet age-related macular degeneration, decrease 25% in ...

France's CAC 40 fell 1.8%, and Germany's DAX dropped 1.7%, underlining the significant impact the new measures are having across Europe's largest economies.